OptimizeRx Corp (OPRX) — Titan Protect Analysis

OPRX

OptimizeRx Corp

Healthcare · ·

$5.11

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$94M

Total market value of the company

Trailing P/E

13.94

Reasonably valued

Forward P/E

4.75

Based on estimated future earnings — lower means cheaper

Rev Growth

-9.5%

Year-over-year revenue change

Profit Margin

6.4%

How much profit the company keeps from each dollar of revenue

ROE

5.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.50

+105% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About OptimizeRx Corp

OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribu

https://www.optimizerx.com

Country: United States Employees: 132 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.013

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0146

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.408

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-31.7%

Historical annualised return based on price data

Max Drawdown

-77.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.19

Moves slightly more than the broader market

52W High

$22.25

77% below the year high

52W Low

$4.57

12% above the year low

Avg Volume

533,250

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.36

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

18.30

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

70.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

2.0%

Profit from core operations before interest and tax

Free Cash Flow

$11M

Positive — the business generates more cash than it spends

Revenue (TTM)

$107M

Total revenue over the last 12 months

Net Income

$7M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$10.50

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go